Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 109

1.

Tobacco Smoking: Risk to Develop Addiction, Chronic Obstructive Pulmonary Disease, and Lung Cancer.

Santoro A, Tomino C, Prinzi G, Lamonaca P, Cardaci V, Fini M, Russo P.

Recent Pat Anticancer Drug Discov. 2019;14(1):39-52. doi: 10.2174/1574892814666190102122848.

PMID:
30605063
2.

Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors.

Rossi S, Toschi L, Finocchiaro G, Di Noia V, Bonomi M, Cerchiaro E, Ceresoli GL, Beretta GD, D'Argento E, Santoro A.

Clin Lung Cancer. 2019 Mar;20(2):82-87. doi: 10.1016/j.cllc.2018.10.009. Epub 2018 Nov 2.

PMID:
30473385
3.

Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Placebo with Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.

Buttigliero C, Shepherd FA, Barlesi F, Schwartz B, Orlov S, Favaretto AG, Santoro A, Hirsh V, Ramlau R, Blackler AR, Roder J, Spigel D, Novello S, Akerley W, Scagliotti GV.

Oncologist. 2018 Aug 23. pii: theoncologist.2018-0089. doi: 10.1634/theoncologist.2018-0089. [Epub ahead of print]

PMID:
30139835
4.

NGR-hTNF and Doxorubicin as Second-Line Treatment of Patients with Small Cell Lung Cancer.

Gregorc V, Cavina R, Novello S, Grossi F, Lazzari C, Capelletto E, Genova C, Salini G, Lambiase A, Santoro A.

Oncologist. 2018 Oct;23(10):1133-e112. doi: 10.1634/theoncologist.2018-0292. Epub 2018 Aug 3.

5.

Failure of ulipristal acetate treatment as an indication for uterine malignancy: Two case reports.

Santoro A, Angelico G, Arciuolo D, Inzani F, Fanfani F, Romualdi D, Scambia G, Zannoni GF.

Medicine (Baltimore). 2018 Aug;97(31):e11532. doi: 10.1097/MD.0000000000011532.

6.

The efficacy of Stereotactic body radiation therapy and the impact of systemic treatments in oligometastatic patients from prostate cancer.

Franzese C, Zucali PA, Di Brina L, D'Agostino G, Navarria P, Franceschini D, Santoro A, Scorsetti M.

Cancer Med. 2018 Sep;7(9):4379-4386. doi: 10.1002/cam4.1707. Epub 2018 Aug 2.

7.

Survival Outcome and Prognostic Factors After Pulmonary Metastasectomy in Sarcoma Patients: A 18-Year Experience at a Single High-volume Referral Center.

Cariboni U, De Sanctis R, Giaretta M, Voulaz E, Morenghi E, Colombo P, Novellis P, Bottoni E, Errico V, Crepaldi A, Marrari A, Navarria P, Ascolese AM, Testori A, Scorsetti M, Quagliuolo V, Santoro A, Alloisio M.

Am J Clin Oncol. 2019 Jan;42(1):6-11. doi: 10.1097/COC.0000000000000476.

PMID:
30048248
8.

Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.

Grossi F, Crinò L, Logroscino A, Canova S, Delmonte A, Melotti B, Proto C, Gelibter A, Cappuzzo F, Turci D, Gamucci T, Antonelli P, Marchetti P, Santoro A, Giusti S, Di Costanzo F, Giustini L, Del Conte A, Livi L, Giannarelli D, de Marinis F.

Eur J Cancer. 2018 Sep;100:126-134. doi: 10.1016/j.ejca.2018.05.015. Epub 2018 Jul 13.

PMID:
30014881
9.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators.

Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.

PMID:
29545095
10.

Checkpoint inhibitors: 'raising the bar' also in brain metastases from non-small-cell lung cancer?

Rossi S, Finocchiaro G, Marchetti S, Toschi L, Santoro A.

Immunotherapy. 2018 Apr;10(5):403-410. doi: 10.2217/imt-2017-0151.

PMID:
29473467
11.

Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come.

Toschi L, Rossi S, Finocchiaro G, Santoro A.

Ecancermedicalscience. 2017 Nov 30;11:787. doi: 10.3332/ecancer.2017.787. eCollection 2017. Review.

12.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL.

J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4.

PMID:
28976790
13.

Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.

Zucali PA, Lopci E, Ceresoli GL, Giordano L, Perrino M, Ciocia G, Gianoncelli L, Lorenzi E, Simonelli M, De Vincenzo F, Setti LR, Bonifacio C, Bonomi M, Bombardieri E, Chiti A, Santoro A.

Cancer Med. 2017 Oct;6(10):2287-2296. doi: 10.1002/cam4.1182. Epub 2017 Sep 21.

14.

Outcome appraisal of patients with limited brain metastases (BMs) from non small cell lung cancer (NSCLC) treated with different local therapeutic strategies: a single institute evaluation.

Pessina F, Navarria P, Cozzi L, Tomatis S, Ascolese AM, Franzese C, Toschi L, Santoro A, De Rose F, Franceschini D, Bello L, Scorsetti M.

Br J Radiol. 2017 Apr;90(1072):20170022. doi: 10.1259/bjr.20170022. Epub 2017 Mar 3.

15.

Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma.

Infante M, Morenghi E, Bottoni E, Zucali P, Rahal D, Morlacchi A, Ascolese AM, De Rose F, Navarria P, Crepaldi A, Testori A, Voulaz E, Errico V, Perrino M, Scorsetti M, Chiti A, Santoro A, Alloisio M.

Eur J Cardiothorac Surg. 2016 Dec;50(6):1077-1082. doi: 10.1093/ejcts/ezw215. Epub 2016 Jun 21.

PMID:
27330149
16.

Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.

Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, Marchetti S, Cortese N, Qehajaj D, Pistillo D, Alloisio M, Roncalli M, Allavena P, Santoro A, Marchesi F, Chiti A.

Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61. doi: 10.1007/s00259-016-3425-2. Epub 2016 Jun 1.

PMID:
27251642
17.

Lung cancer screening with low-dose spiral computed tomography: evidence from a pooled analysis of two Italian randomized trials.

Infante M, Sestini S, Galeone C, Marchianò A, Lutman FR, Angeli E, Calareso G, Pelosi G, Sozzi G, Silva M, Sverzellati N, Cavuto S, La Vecchia C, Santoro A, Alloisio M, Pastorino U.

Eur J Cancer Prev. 2017 Jul;26(4):324-329. doi: 10.1097/CEJ.0000000000000264.

PMID:
27222939
18.

Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study.

Falanga A, Santoro A, Labianca R, De Braud F, Gasparini G, D'Alessio A, Barni S, Iacoviello L; HYPERCAN Study Group.

Thromb Res. 2016 Apr;140 Suppl 1:S55-9. doi: 10.1016/S0049-3848(16)30099-8.

PMID:
27067979
19.

Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer.

Scorsetti M, Franceschini D, De Rose F, Comito T, Villa E, Iftode C, Navarria P, D'Agostino GR, Masci G, Torrisi R, Testori A, Tinterri C, Santoro A.

Breast. 2016 Apr;26:11-7. doi: 10.1016/j.breast.2015.12.002. Epub 2016 Jan 3.

PMID:
27017237
20.

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.

Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT.

Lancet Oncol. 2016 Apr;17(4):452-463. doi: 10.1016/S1470-2045(15)00614-2. Epub 2016 Mar 11.

Supplemental Content

Loading ...
Support Center